• Intuitive Surgical (NasdaqGS:ISRG) reported strong Q1 2026 results with a significant beat on earnings and revenue expectations.
• Procedure volumes rose 17%, with recurring revenue making up a substantial portion of total sales.
• The company expanded its installed base of da Vinci and Ion systems and introduced new digital and AI-enabled features.
• Additional FDA clearances supported the company’s position following recent recalls and regulatory scrutiny.

Intuitive Surgical focuses on robotic assisted surgery through its da Vinci and Ion platforms, which operate at the intersection of medical devices, software, and data. For investors watching the broader move toward minimally invasive procedures and digital tools in the operating room, Q1 2026 shows how these trends are contributing to greater use of the company’s installed systems and related services.

With procedure growth at 17% and recurring revenue forming a meaningful share of sales, the latest quarter reflects a business that relies heavily on ongoing usage rather than one-off hardware placements. The combination of system growth, AI-enabled features, and additional FDA clearances provides more concrete data points to monitor when assessing how Intuitive Surgical is positioning its platforms in light of demand and regulatory expectations.

Stay updated on the most important news stories for Intuitive Surgical by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Intuitive Surgical.

For investors, Intuitive Surgical’s Q1 2026 report gives hard numbers behind the story of growing robotic assisted surgery. Revenue of US$2.77b, up from US$2.25b a year earlier, and net income of US$821.5m versus US$698.4m, show that higher procedure volumes and a larger installed base are feeding through to both the top and bottom line. Basic EPS from continuing operations moved from US$1.95 to US$2.31, while diluted EPS rose from US$1.92 to US$2.28, which indicates that earnings strength was not just optical from share count changes. With recurring revenue at 86% of total sales and procedure volumes up 17%, the quarter points to a business that is increasingly driven by ongoing instrument, accessory, and service usage rather than one off system sales.

How This Fits Into The Intuitive Surgical Narrative

• The Q1 revenue and earnings, supported by 17% procedure growth and high recurring revenue, align with the narrative that expanding global adoption and higher system utilization are key drivers of long term earnings power.
• Ongoing FDA recalls of da Vinci S/Si reusable instruments and stapler safety reviews push against the narrative’s assumption of smooth regulatory and payer support, since they introduce potential reputational and operational friction.
• The step up in AI enabled and digital capabilities mentioned around Q1 is only partially reflected in the narrative’s focus on product and digital tools, and may not fully capture how these features could influence surgeon behavior and competitive positioning versus players like Medtronic, Johnson & Johnson, and Stryker.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Intuitive Surgical to help decide what it is worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ The series of voluntary recalls for certain da Vinci instruments and FDA review of curved tip staplers highlight product quality and regulatory risk that could influence hospital purchasing decisions or utilization over time.
• ⚠️ Analysts cutting price targets while keeping positive or neutral ratings signals that valuation expectations and sector rotation risk remain live issues even when quarterly results are strong.
• 🎁 Q1 revenue of US$2.77b and net income of US$821.5m, both above the prior year, alongside an EPS beat versus several consensus estimates, support the view that procedure growth and installed base expansion are feeding through to earnings.
• 🎁 Recurring revenue at 86% of total sales, backed by 17% procedure growth and broad adoption of da Vinci and Ion platforms, underlines a usage based model that can provide more predictable cash flows than pure hardware cycles.

What To Watch Going Forward

From here, investors may want to watch whether procedure growth and system placements remain broad based across regions and specialties, and whether recurring revenue continues to represent a similar share of total sales. The way hospitals respond to recalls of reusable instruments, and any further FDA communication on staplers or other products, will also be important for gauging regulatory risk. Finally, pay attention to how quickly AI enabled features and digital tools are adopted in operating rooms, and to how competitors such as Medtronic, Johnson & Johnson, and Stryker position their own robotic platforms and digital ecosystems in response.

To stay up to date on how the latest news impacts the investment narrative for Intuitive Surgical, head to the community page for Intuitive Surgical to follow the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.